Back to Search
Start Over
Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma
- Source :
- The Cancer Journal. 16:360-366
- Publication Year :
- 2010
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2010.
-
Abstract
- Food and Drug Administration-approved treatment for metastatic melanoma, including interferon alpha and interleukin-2, offer a modest benefit. Immunotherapy, although has not enjoyed high overall response rates, is capable of providing durable responses in a subset of patients. In recent years, new molecular-targeted therapies have become available and offer promise of clinical benefit, although low durability of response. It is not yet clear how best to integrate these 2 novel modalities that target the immune response to melanoma (immune therapy) or that target molecular signaling pathways in the melanoma cells (targeted therapy). Many signal transduction pathways are important in both tumor cell and T-cell proliferation and survival, which generate risk in combining targeted therapy and immunotherapy. This review focuses on the role of targeted therapy and immunotherapy in melanoma, and discusses how to combine the 2 modalities rationally for increased duration and response.
- Subjects :
- Drug
Cancer Research
medicine.medical_treatment
media_common.quotation_subject
Alpha interferon
Cancer Vaccines
Article
Targeted therapy
Immune system
Signal Transduction Inhibition
medicine
Animals
Humans
Molecular Targeted Therapy
Melanoma
media_common
business.industry
Immunotherapy
medicine.disease
Combined Modality Therapy
Oncology
Immunology
Cancer research
Signal transduction
business
Signal Transduction
Subjects
Details
- ISSN :
- 15289117
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- The Cancer Journal
- Accession number :
- edsair.doi.dedup.....1b48e2ea6f3f62cabbf619c93676ed9e